Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibi...

Full description

Saved in:
Bibliographic Details
Published inJTO clinical and research reports Vol. 5; no. 4; p. 100657
Main Authors Torasawa, Masahiro, Yoshida, Tatsuya, Shiraishi, Kouya, Goto, Naoko, Ueno, Toshihide, Ichikawa, Hitoshi, Yagishita, Shigehiro, Kohsaka, Shinji, Goto, Yasushi, Yatabe, Yasushi, Hamada, Akinobu, Mano, Hiroyuki, Ohe, Yuichiro
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.04.2024
Elsevier
Subjects
Case report
Disease flare
Lenvatinib
Thymic carcinoma
Case report
Lenvatinib
Disease flare
Thymic carcinoma
Online AccessGet full text

Cover

More Information
Summary:Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2024.100657